Clinical trials: Elderly Lymphoma Patients
Graft vs Host Disease, Myelodysplastic Syndromes
Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS
This study will evaluate the safety and effectiveness of stem cell transplantation in which the donors T lymphocytes have undergone "selective depletion." Certain patients with cancers of the blood undergo transplantation of…
- Conditions
- Graft vs Host Disease, Myelodysplastic Syndromes, Leukemia, Leukemia, Myeloid
- Trial name
- NCT00025662
- Testing
- RFT5-SMPT-dgA, Isolex system
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Lymphoma, Non-Hodgkin, Lymphoma, Follicular
Ofatumumab In Older Patients With Untreated Low Or Intermediate Risk Indolent B-Cell Lymphomas
This research study will only include two types of non-Hodgkin Lymphoma (NHL), follicular lymphoma or marginal zone lymphoma and participants will be age 70 or older.
- Conditions
- Lymphoma, Non-Hodgkin, Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Low-Grade
- Trial name
- NCT01263418
- Testing
- Ofatumumab
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Diffuse Large B-Cell Lymphoma
Bendamustine, Obinutuzumab, and Dexamethasone in Older Patients With Diffuse Large B-cell Lymphoma
This phase II trial studies how well bendamustine hydrochloride, obinutuzumab, and dexamethasone work in treating older patients with diffuse large B-cell lymphoma.
- Trial name
- NCT02420210
- Testing
- Bendamustine Hydrochloride, Obinutuzumab, Dexamethasone
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Chicago
Lymphoma
Oral Combination Chemotherapy in Treating Elderly Patients With Intermediate or High-Grade Non-Hodgkin's Lymphomas
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving the drugs in different ways may kill more tumor cells.
- Trial name
- NCT00003113
- Testing
- filgrastim, cyclophosphamide, etoposide
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Case Comprehensive Cancer Center
Mantle Cell Lymphoma
PirtobrUtinib as Frontline Therapy for Elderly Unfit/Frail Patient With MAntle Cell Lymphoma
This is a prospective, multicenter, phase II study, in elderly patients affected by Mantle cell lymphoma (MCL) defined as unfit/frail according to Simplified Geriatric Assessment (sGA) and previously untreated.
- Trial name
- FIL_PUMA (NCT07207785)
- Testing
- Pirtobrutinib
- Where
- 20 sites in Italy
- Volunteers
- 56 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Diffuse Large B Cell Lymphoma
Prospective Clinical Study of ZPR Regimen in Elderly Treatment-naive Diffuse Large B-cell Lymphoma
This is a prospective, single-arm, single-center clinical study. This clinical study aims to explore the efficacy and safety of the ZPR（Zanubrutinib, Polatuzumab vedotin and Rituximab）regimen in elderly patients with…
- Trial name
- NCT05940064
- Testing
- Zanubrutinib, Polatuzumab Vedotin, Rituximab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peng Liu
Non-Hodgkins Lymphoma
Combination Chemotherapy and Rituximab With Pegfilgrastim Followed by Rituximab, in Large B-Cell Non-Hodgkin's Lymphoma
The purposes of this trial are to decrease toxicity and improve treatment effectiveness elderly patients. With a short course of chemotherapy with cyclophosphamide, mitoxantrone, vincristine, and prednisone with concurrent…
- Trial name
- NCT00193479
- Testing
- Cyclophosphamide, Mitoxantrone, Vincristine
- Where
- 2 sites in United States
- Volunteers
- 51 people
- Sponsor
- SCRI Development Innovations, LLC
Diffuse Large B Cell Lymphoma
Trial of R-GemOx Versus R-miniCHOP Regimen in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma
The purpose of this study is to investigate efficacy and safety of R-GemOx Versus R-miniCHOP as first-line treatment of elderly patients with Diffuse large B cell lymphoma
- Trial name
- NCT02767674
- Testing
- Rituximab, Gemcitabine, Oxaliplatin
- Where
- 6 sites in China
- Volunteers
- 258 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Non-GCB/ABC Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma
Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCL
Aim of this study will evaluate the efficacy and safety of tislelizumab in combination with lenalidomide in in patients with relapsed or refractory Elderly Patients with non-GCB Diffuse Large B Cell Lymphoma
- Conditions
- Non-GCB/ABC Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma Grade IIIb, Transformed Lymphoma
- Trial name
- NCT04796857
- Testing
- PD-1 Antibody, Lenalidomide
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Huiqiang Huang
CCND1 Positive, CCND2 Positive
Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma
This phase II trial studies how well ibrutinib and rituximab work in treating patients with mantle cell lymphoma that has come back or has not responded to treatment or older patients with newly diagnosed mantle cell lymphoma.
- Conditions
- CCND1 Positive, CCND2 Positive, CCND3 Positive, CD20 Positive
- Trial name
- NCT01880567
- Testing
- Ibrutinib, Laboratory Biomarker Analysis, Rituximab
- Where
- United States
- Volunteers
- 113 people
- Sponsor
- M.D. Anderson Cancer Center
Diffuse Large Cell Lymphoma
ACVBP Plus Rituximab in Patients Aged From 18 to 59 Years With High-risk Diffuse Large B-cell Lymphoma
This study is a multicentric trial evaluating the efficacy of R-ACVBP in patients aged 18 to 59 years with high risk diffuse large B-cell lymphoma
- Trial name
- NCT00144807
- Testing
- rituximab, doxorubicin, cyclophosphamide
- Where
- 13 sites in Belgium, France and 1 more
- Volunteers
- 128 people
- Sponsor
- Lymphoma Study Association
Lymphoma
Rituximab and Combination Chemotherapy in Treating Older Patients With Previously Untreated B-Cell Lymphoma
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some find cancer cells and kill them or carry cancer-killing substances to them.
- Trial name
- NCT00290667
- Testing
- pegfilgrastim, rituximab, cyclophosphamide
- Where
- 338 sites in Czechia, France and 7 more
- Volunteers
- 586 people
- Sponsor
- German High-Grade Non-Hodgkin's Lymphoma Study Group
Follicular Lymphoma
BRIEF Bendamustine and Rituximab In Elderly Follicular
The objective of this study is to evaluate the complete response rate after a short induction treatment with rituximab (375mg/m2)and bendamustine (90mg/m2)in In Elderly (≥ 60 years old) patients with untreated Follicular…
- Trial name
- BRIEF (NCT01313611)
- Testing
- Rituximab + bendamustine
- Where
- 117 sites in Belgium, France
- Volunteers
- 62 people
- Sponsor
- The Lymphoma Academic Research Organisation
Primary Central Nervous System Lymphoma
Adjusted High-dose Chemotherapy With Autologous Stem Cell Transplant vs. Conventional Immunochemotherapy in Elderly PCNSL Patients
Most patients being diagnosed with primary diffuse large B-cell lymphoma of the central nervous system (PCNSL) are 60 years or older.
- Trial name
- PRIMA-CNS (NCT06830421)
- Testing
- R-MP and Procarbazine maintenance, R-MTX/AraC (MARTA) induction followed by consolidating HCT-ASCT
- Where
- 35 sites in Germany
- Volunteers
- 340 people
- Sponsor
- University Hospital Freiburg
Diffuse Large B Cell Lymphoma
Zanubrutinib, Lenalidomide and Rituximab (ZR2) in Elderly Treatment-naive Patients With Diffuse Large B-cell Lymphoma (DLBCL)
This is a prospective, single-center, open-label, single-arm clinical study designed to evaluate the efficacy and safety of the Zanubrutinib, Lenalidomide and Rituximab (ZR2) regimen in elderly treatment-naive patient with…
- Trial name
- NCT04460248
- Testing
- Zanubrutinib, Lenalidomide and Rituximab (ZR2)
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Ruijin Hospital
Untreated CD20-positive Large B-cell Lymphoma
Study of R-ACVBP Regimen Supported by Pegfilgrastim in High-Risk Diffuse Large B-Cell Lymphoma
Evaluation of the efficacy of a single injection of Pegfilgrastim (6mg) administered at day 3 of each cycle of R-ACVBP regimen during 4 cycles in patients with CD20+ diffuse large B-cell lymphoma presenting at least 2 adverse…
- Trial name
- NCT00169143
- Testing
- Rituximab + ACVBP regimen plus Pegfilgrastim, Autologous stem cell transplant
- Where
- 6 sites in France
- Volunteers
- 60 people
- Sponsor
- Lymphoma Study Association
Diffuse Large B Cell Lymphoma
Polatuzumab, Rituximab and Orelabrutinib Combination Regimen (PRO) in the Treatment of Elderly Frail Patients with Treatment-naive Non-GCB DLBCL
This prospective, single-arm, multicenter clinical study aims to enroll 30 frail elderly patients with Non-GCB DLBCL. This study is to evaluate the preliminary efficacy and safety of the combination of Polatuzumab, Rituximab, and…
- Trial name
- NCT06530511
- Testing
- Polatuzumab vedotin, Rituximab, Orelabrutinib
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Affiliated Hospital of Nantong University
Mantle Cell Lymphoma
Acalabrutinib and Rituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma
This phase II trial studies the side effects of acalabrutinib and rituximab and its effect in treating patients with previously untreated mantle cell lymphoma.
- Trial name
- NCT04765111
- Testing
- Acalabrutinib, Rituximab
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- M.D. Anderson Cancer Center
DLBCL, Diffuse Large B-Cell Lymphoma
Clinical Study of HiR+X Therapy for Newly Diagnosed Elderly Patients With DLBCL Intolerant to Chemotherapy
To explore the application of HiR (Zebtorizumab, Lenalidomide) + X (targeted drug) guided by NGS molecular typing, the aim is to assess the therapeutic efficacy and safety in newly diagnosed unfit or frail elderly patients with…
- Trial name
- HiR+X (NCT06758037)
- Testing
- Drug therapy
- Where
- China
- Volunteers
- 50 people
- Sponsor
- First Affiliated Hospital of Ningbo University
Diffuse Large Cell Lymphoma
ACVBP Versus ACVBP Plus Rituximab in Low Risk Localized Diffuse Large B-cell Lymphoma
This study is a multicentric randomized trial evaluating the efficacy of the combination R-ACVBP in patients 18 to 65 years with low risk localized diffuse large B-cell lymphoma.
- Trial name
- NCT00140660
- Testing
- rituximab
- Where
- 11 sites in Belgium, France and 1 more
- Volunteers
- 223 people
- Sponsor
- Lymphoma Study Association